Last edition
News about "investigational therapy"
INTENT Biologics Secures FDA Breakthrough Therapy Tag for Diabetic Foot Ulcer Treatment Candidate
INTENT Biologics' PEP Biologic receives FDA Breakthrough Therapy designation for diabetic foot ulcers, accelerating development of its first-in-class exosome-based regenerative treatment aimed at improving healing outcomes in chronic wounds.
Investigational Therapy | 03/07/2026 | By News Bureau | 148
Axsome Doses First Patient in Phase 3 Trial of Solriamfetol for Adolescent ADHD
Axsome Therapeutics has initiated patient dosing in the Phase 3 FOCUS-3 trial evaluating solriamfetol as a potential treatment for adolescents with Attention Deficit Hyperactivity Disorder.
Investigational Therapy | 01/07/2026 | By News Bureau
GCAR and Purdue Pharma Launch Tinostamustine in GBM AGILE Trial
GCAR and Purdue Pharma LP initiate Tinostamustine enrolment in the GBM AGILE Phase 2/3 trial, advancing potential new treatment options for glioblastoma patients.
Investigational Therapy | 09/04/2026 | By News Bureau
Biohaven Completes Enrollment in Phase II Trial of Taldefgrobep for Obesity
Biohaven finishes enrollment in Phase II study of taldefgrobep, a novel therapy targeting fat loss and muscle gain, with topline data expected in the second half of 2026.
Investigational Therapy | 21/03/2026 | By News Bureau | 291
GentiBio Doses First Patient in Phase I Trial of Novel Cell Therapy for Type 1 Diabetes
GentiBio initiates Phase I POLARIS trial of GNTI-122, an engineered Treg therapy aimed at preserving insulin production and reducing lifelong insulin dependence in newly diagnosed type 1 diabetes patients.
Investigational Therapy | 19/03/2026 | By News Bureau | 152
Roche reported positive late-breaking Phase III ACTRIMS data showing fenebrutinib reduced disability progression in Primary Progressive Multiple Sclerosis (PPMS), demonstrating non-inferiority to OCREVUS and reinforcing its potential as a first-in-class oral BTK inhibitor.
Investigational Therapy | 09/02/2026 | By News Bureau | 179
ALS Association Announces USD 2M Support for Emerging ALS Treatments
The ALS Association has awarded $2 million through its Hoffman ALS Clinical Trial Awards Program to advance two early-stage therapeutic candidates, supporting efforts to accelerate the development of new treatments for the disease.
Investigational Therapy | 06/12/2025 | By Dineshwori | 279
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy